Exhibit 99.1

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points

75% of CSU participants (n=36) enrolled in the open label extension study achieved a complete response or well controlled disease at 12 weeks

With a median duration of follow up of more than 200 days on 63 participants in the open label extension study, KIT related AEs were low in frequency and predominantly low-grade events that resolved while on study

BEACON and open label extension data sets are now sufficient to select doses for the Phase 2b study of briquilimab in CSU planned to commence in the second half of 2026

Company to host conference call and webinar today at 8:00 a.m. ET

REDWOOD CITY, Calif., January 8, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is reporting positive updated clinical data from Jasper’s BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with CSU, as well as from the open label extension study in CSU and CIndU. Treatment with briquilimab resulted in rapid disease control in the additional participants enrolled in the 240mg / 180mg Q8W cohort (n=6) in the BEACON study, with 83% of participants achieving a complete response by week 3 after the initial 240mg dose, and 67% reporting a complete response at 12 weeks. Similarly high levels of efficacy were demonstrated in the open-label extension study evaluating a 180mg Q8W dosing regimen, with 58% of CSU participants (n=36) achieving a complete response at 12 weeks.

“We are very pleased to present data from additional patients enrolled in the BEACON study, which reaffirms the potential of briquilimab to drive rapid and durable disease control in patients with CSU,” said Dr. Daniel Adelman, Acting Chief Medical Officer of Jasper. “We are also pleased by the performance of the 180mg Q8W dose in the open label extension study, with the strong efficacy observed in CSU and CIndU patients. Taken together with the favorable safety and tolerability profile observed in both studies, we believe these data are sufficient to support a differentiated profile for briquilimab in chronic urticaria. On behalf of the Jasper team, I’d like to thank the investigators and the patients who participated in the study, along with their families and caregivers.”

BEACON Study Design and Updated Data Summary:

The BEACON study is a randomized, double-blind, and placebo-controlled Phase 1b/2a trial evaluating multiple ascending doses of subcutaneous briquilimab as a therapy for adult patients with moderate to severe CSU despite treatment with high dose antihistamines. The primary endpoints are safety and tolerability of briquilimab and secondary endpoints are focused on clinical activity and PK/PD, including measurement of serum tryptase and mast cells in skin. Primary measurements used to assess clinical activity were the sum of the Hives Severity Score and the daily Itch Severity Score (ISS), as measured via the Urticaria Activity Score over 7 days (UAS7) on a 0 to 42-point scale.

The updated data includes the results from 8 additional participants enrolled into the 240mg /180mg Q8W cohort of the BEACON study since the last data update in July 2025, with 2 of those participants randomized to placebo. In patients dosed with briquilimab (n=6), the mean reduction from baseline in the UAS7 score was 31.0 points at 12 weeks. By week 3, complete responses (UAS7 = 0) were achieved by 83% of participants dosed with briquilimab, and at week 12, 67% of participants dosed with briquilimab reported complete responses.

Briquilimab continued to be well-tolerated in the BEACON study, with no dose limiting toxicities observed. Safety observations potentially related to KIT blockade were infrequent and generally limited to low grade events, none of which resulted in discontinuations or dose delays and the majority of which resolved during repeat dosing.

Open Label Extension Study Design and Updated Data Summary:

The open-label extension study in chronic urticarias is enrolling patients with CSU from the BEACON study as well as patients with CIndU from the SPOTLIGHT study who have completed study follow up. Participants in the open label extension are treated with 180mg of briquilimab on a Q8W dosing schedule. Jasper is reporting efficacy data from 36 patients with CSU and 17 patients with CIndU, all of whom completed at least 12 weeks of follow-up.

Briquilimab treatment continued to drive deep and durable disease control in the open label extension. At the 12 week assessment, 58% of CSU patients (n=36) achieved a complete response and 75% achieved either complete response or well controlled disease (UAS7≤6). In the CIndU portion of the open label extension study, efficacy measurements were taken every 8 weeks, and 65% of patients (n=17) achieved a complete response or partial response at 16 weeks, which was 8 weeks following administration of the second dose.

With a median duration of follow up of 205 days in 63 patients (46 CSU and 17 CIndU) briquilimab continued to be well-tolerated with no dose limiting toxicities observed. Safety observations potentially related to KIT blockade were infrequent and generally limited to low grade events, none of which resulted in discontinuations or dose delays and the majority of which resolved during repeat dosing.

“We are excited to present positive updated data from our chronic urticaria studies,” said Jeet Mahal, President and Chief Executive Officer of Jasper. “With the rapid onset of disease control, durable efficacy and a favorable safety profile supported by more than six months median follow up in more than 63 patients, briquilimab continues to demonstrate the potential for a compelling and differentiated product profile to address the high level of unmet need for patients with chronic urticaria. With these additional data from the BEACON and open label extension studies, we now have sufficient efficacy and safety data to enable dose selection for our planned Phase 2b study in CSU, which we expect to commence in the second half of 2026.”

Conference Call / Webinar

Jasper will host a conference call and webinar today at 8:00 a.m. ET. A live question and answer session with management will follow the formal presentation. A link to the webinar, including presentation slides, can be found here.

The presentation slides and a link to the live and archived webcast will also be available on the Events & News – Events page of Jasper's Investor Relations website.

About Jasper

Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor KIT, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU, CIndU and asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in CSU, CIndU and allergic asthma. For more information, please visit us at www.jaspertx.com.

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab’s potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU and asthma, its potential to drive rapid and durable disease control in patients with CSU and the potential for a compelling and differentiated product profile to address the high level of unmet need for patients with chronic urticaria; briquilimab’s safety profile; the sufficiency of the data to support a differentiated profile for briquilimab in chronic urticaria; briquilimab’s ability to drive deep and durable disease control Jasper’s expectations regarding a registrational program in CSU, including the expected timing of the Phase 2b study and dose selection; ; and the topics expected to be discussed during the webinar. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper may be unable to raise capital to continue its operations and continue the BEACON study; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated, including the updated results for the BEACON study and open-label extension study reported in this press release; the risk that Jasper’s product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper’s assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Contacts:

Alex Gray (investors)
Jasper Therapeutics
650-549-1454 
agray@jaspertherapeutics.com

Joyce Allaire (investors)
LifeSci Advisors
617-435-6602
jallaire@lifesciadvisors.com

Media:
media@jaspertx.com  

4

Exhibit 99.2

Jasper Therapeutics BEACON & OLE Data Update January 8, 2026 Exhibit 99.2

2 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Safe Harbor Statements Forward - Looking Statements This investor presentation and any accompanying oral presentation (together, this “Presentation”) contain forward - looking statements. All statements other than statements of historical fact contained in this Presentation, including statements regarding the future opportunities and prospects of Jasper Therapeutics, Inc. (together with its subsidiary, "Jasper" or the "Company"), including milestones, potential regulatory filings and the anticipated timing thereof, patient enrollment, future timelines, business strategy, and plans and objectives for future operations, are forward - looking statements. Jasper has based these forward - looking statements on its estimates and assumptions and its current expectations and projections about future events. These forward - looking statements are subject to a number of risks, uncertainties and assumptions, including those contained in the "Risk Factors" section of the Company's Annual Report on Form 10 - K for the year ended December 31, 2024, Quarterly Reports on Form 10 - Q and Current Reports on Form 8 - K that the Company has subsequently filed or may subsequently file with the SEC. In light of these risks, uncertainties and assumptions, the forward - looking events and circumstances discussed in this Presentation are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward - looking statements. Accordingly, you should not rely upon forward - looking statements as predictions of future events. Jasper undertakes no obligation to update publicly or revise any forward - looking statements for any reason after the date of this Presentation or to conform these statements to actual results or to changes in Jasper's expectations. Industry and Market Data Certain data in this Presentation was obtained from various external sources, and neither the Company nor its affiliates, advisers or representatives has verified such data with independent sources. Accordingly, neither the Company nor any of its affiliates, advisers or representatives makes any representations as to the accuracy or completeness of that data or undertakes any obligation to update such data after the date of this Presentation. Such data involves risks and uncertainties and is subject to change based on various factors. Trademarks The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of the Company.

3 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION New BEACON and OLE data support advancing into a Phase 2b CSU study in 2H 2026 Briquilimab’s unique drug properties allow for rapid clinical efficacy while minimizing KIT related AEs • Briquilimab’s MOA (direct ligand/receptor blockade) and high Cmax leads to rapid mast cell depletion with deep UAS7 reduction and disease control in first 2 - 4 weeks • Drug clearance near end of 8 week dosing cycle allows for reduction of KIT related AEs and improved profile for patients Briquilimab continues to demonstrate rapid and durable clinical responses • 10 additional patients enrolled in the BEACON study – Eight (6 briquilimab + 2 placebo) in Cohort 9.1(240mg 180mg Q8W) and 2 in Cohort 8.1(240mg Q8W) • New Cohort 9.1: 83% (5 of 6) of briquilimab patients achieved a CR by week 3, with 67% (4 of 6) CRs at 12 weeks Briquilimab was well tolerated and demonstrates a favorable chronic safety profile • OLE (n=63, 180mg Q8W median duration > 200 days) shows deepening efficacy with low incidence of KIT related AEs Data support commencing a Phase 2b study as part of a CSU registrational program in 2H 2026 • Phase 2b study expected to be a 75 - 100 patient multi - site study evaluating two effective dose regimens vs. placebo Briquilimab continues to demonstrate differentiated efficacy & safety profile

BEACON & OLE Data Update Dr. Daniel Adelman, Acting CMO Jasper Therapeutics Open - Label Extension Study +

5 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION January 2026 BEACON Study & OLE Study Data Update Briquilimab continues to demonstrate rapid and durable clinical responses • BEACON Cohort 9.1 patients reaffirms strong efficacy and safety profile • Mean reduction in UAS7 scores of 31 points at week 12 • Rapid onset of effect with CR or well controlled disease reported in the majority of patients by week 2 • 83% (5 of 6) of patients achieved a CR at week 3 after initial 240mg loading dose • 67% (4 of 6) of patients reported a CR at week 12 on the 180mg maintenance dose • CIndU OLE – Durable clinical response demonstrated in CIndU patients with repeat - dose briquilimab • 65% (11 of 17) of CIndU patients achieved CR or PR at week 16 (8 weeks from last dose) • CSU OLE – Progressive UAS7 reductions over time supports potential for a maintenance dose in CSU • 75% (27 of 36) of patients achieved CR or WC disease at 12 weeks Briquilimab continues to demonstrate the potential for a differentiated safety profile Data gathered to - date sufficient to enable final dose selection for CSU Phase 2b study

6 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION • UAS7 ≥ 16 • 18+ years Screening/Eligibility • CSU diagnosis ≥ 6 mos. • H1 - antihistamine - failed Study Operations • US Lead: Tom Casale, MD • EU Lead: Martin Metz, MD • ~30 sites in the US & EU Key Assessments • Disease Scores: UAS7, UCT • Safety: TEAEs, SAEs • PK • Mast Cell Depletion & Recovery: Serum Tryptase, Skin Biopsies Phase 1b/2a BEACON Study in Chronic Spontaneous Urticaria Randomized, Double - Blind, Placebo - Controlled, Multiple Ascending Dose Study Pa t i e n t s (Randomization) Dose Sch e du l e n=3+3 per dose n=8 (3:1) 10mg & 40mg 80mg Open Label (n=6) Double - Blind Placebo - Controlled (n=81) Cohorts included in January 2025/July 2025 data cuts Additional patients enrolled since July 2025 data update Weeks 0, 4, 12, 20 Q8W Q8W Q12W Q8W Q12W Single Dose 120mg 180mg 240mg 240mg → 180mg 360mg Single Dose Q8W Cohor t # C1 & C2 C4a C4b C5b C5a C3 C7 n=10 (3:1) n=9 (3:1) n=6 (2:1) n=6 (2:1) Single Dose n=9 (3:1) n=8(3:1) 240mg C6 n=8 (3:1) n=6 (3:1) n=9 (3:1) n=2(3:1) C9 C9.1 C8 C8.1 Q8W Q8W

7 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Rapid and deep reductions in tryptase with initial 240mg or higher dose Data cut - off 2 Jan 2026 Serum Tryptase (ng/ml) 12 10 8 6 4 2 360mg (SD) (n=5) 0 0 1 Placebo (n=21) 240mg Q8W (n=6) 2 4 Week 240mg (SD) (n=6) 240mg - > 180mg Q8W (n=13) 6 8

8 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION New 240mg/180mg Q8W data demonstrate rapid and sustained UAS7 response 31 - point reduction in mean UAS7 score at week 12 with new 9.1 cohort Mean UAS7 0 35 30 25 20 15 10 5 40 0 1 2 3 4 5 6 7 Week 8 9 Placebo (n=21) Cohort 9.1 (n=6, 240 mg 180mg Q8W) 31 pt mean UAS7 reduction at week 12 10 11 12 *Note: At Week 6 in the BEACON study, patients in the placebo arm were allowed rescue medications. Data cut - off 2 Jan 2026

9 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Response (%) 90 80 70 60 50 40 30 20 10 0 100 1 2 3 4 5 6 7 Week 8 9 10 11 12 CR + WC CR New 240mg/180mg Q8W patients demonstrate rapid and durable responses 83% of patients with complete response at week 3 (n=6) Data cut - off 2 Jan 2026

10 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Briquilimab well tolerated with favorable safety profile demonstrated Total Pooled Placebo (N= 21 ) 12 ( 57 . 1 ) Total Pooled Briquilimab (N=64) 4 48 (75) Cohort 9.1 240mg 180mg Q8W (N=6) 6 (100) Cohort 9 240mg 180mg Q8W (N=7) 5 (71.4) Cohort 8 240mg Q8W Briquilimab (N=6) 3 (50) Cohort 7 360mg Briquilimab (N=5) 4 (80) Cohort 6 240mg Briquilimab (N=6) 6 (100) Cohort 5 Pooled 180mg Briquilimab (N=14) 10 (71.4) Number of Participants With: Any TEAE 0 (0) 1 (1.6) 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (7.1) 1 Any Treatment - Related Serious TEAE 0 (0) 2 (3.1) 1,2 0 (0) 1 (14.3) 2 0 (0) 0 (0) 0 (0) 1 (7.1) 1 Any TEAE Leading to Discontinuation of IP 0 (0) 1 (1.6) 3 0 (0) 0 (0) 0 (0) 0 (0) 1 (16.7) 3 0 (0) Any Treatment - Related TEAE ≥ Grade 3 Median duration of follow - up: Cohort 8 – 256 days; Cohort 9 – 211 days; Cohort 9.1 – 95 days Most commonly reported AEs (≥10 participants): nasopharyngitis, neutrophil count decreased, taste disorder, fatigue 1 Single participant, 180mg Q8W, CoFAR grade 2 hypersensitivity reaction 2 Single participant, 240mg D1 180mg Q8W, CoFAR grade 2 hypersensitivity reaction 3 Single participant with Grade 3 neutrophil count decreased, resolved in 14 days 4 Total pooled briquilimab includes 10mg (n=3), 40mg (n=3), 80mg (n=6) and 120mg (n=8) Data cut - off 2 Jan 2026

11 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Safety/tolerability observations possibly related to KIT blockade were generally limited to low grade events Majority resolved during repeat dosing and none resulted in discontinuations or dose delays Pooled Placebo (N= 21 ) 1 ( 4 . 8 % ) Total Pooled Briquilimab (N=64) 4 5 (8.8%) Cohort 9.1 240mg 180mg Q8W (N=6) 0 (0) Cohort 9 240mg 180mg Q8W (N=7) 0 (0) Cohort 8 240mg Q8W Briquilimab (N=6) 1 (16.7%) Cohort 7 360mg Briquilimab (N=5) 0 (0%) Cohort 6 240mg Briquilimab (N=6) 0 (0%) Cohort 5 Pooled 180mg Briquilimab (N=14) 2 (14.3%) Adverse Event as reported term Hair color changes 1 (4.8) 1 (1.6) 3 0 (0) 0 (0) 1 (16.7) 3 0 (0) 0 (0) 0 (0) Skin discoloration 1 (4.8) 11 (17.2) 1 1 (16.7) 2 (28.6) 0 (0) 2 (40) 3 (50) 1 (7.1) Taste change 5 2 (9.5) 15 (23.4) 2 1 (16.7) 2 (28.6) 0 (0) 2 (40) 5 (83.3) 3 (21.4) Neutrophil count decreased Median duration of follow - up: Cohort 8 – 256 days; Cohort 9 – 211 days; Cohort 9.1 – 95 days 1 Median time to resolution of taste change in briquilimab - treated participants was 54 days 2 Median time to resolution of Neutrophil count decreases in briquilimab - treated participants was 15 days 3 Single participant with skin discoloration described as hyperpigmentation 4 Total pooled briquilimab includes 10mg (n=3), 40mg (n=3), 80mg (n=6) and 120mg (n=8) 5 Includes reported terms of taste disorder, hypogeusia, and dysgeusia. Data cut - off 2 Jan 2026

12 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Screening/Eligibility • To enroll, patients from BEACON/SPOTLIGHT must either: • Wait for symptoms to return following dosing (defined as UAS7 ≥ 16 for CSU, UCT ≤ 12 for CIndU) • OR complete the BEACON/SPOTLIGHT study Key Objectives/Enrollment Target • Generate additional safety, efficacy and durability at 180mg Q8W dose schedule for both CSU and CIndU programs Jasper Chronic Urticaria Open Label Extension Study (JSP - CP - 014) Enrolling patients from the BEACON and SPOTLIGHT studies Pa r e n t C U S t u d i e s Tr e a t m e n t Pe r i o d Pre - E n rollment 180mg Q8W Eligibility Check We e k s - 2 0 8 16 24 32 Study End/Treatment Discontinuation Stu d y End

13 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION CIndU OLE: Clinical responses maintained at 24 weeks with 180mg Q8W • 17 CIndU patients rolled over from SPOTLIGHT • Continued to observe a rapid onset of effect: o 11 of 16 patients (69%) achieved either CR or PR by week 2 • Durable effect even at 8 weeks post - dose o 11 of 17 patients (65%) maintained clinical response even at week 16 o Challenge preformed prior to next dose Response Week CR: TFS (Total Fric Score)=0 or CTT (Critical Temperature Threshold)<=4 0 C PR: TFS reduction of 2 or more from baseline or reduction of 4 0 C or more in CTT Data cut - off 11 Dec 2025 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 2 n=16 8 n=17 16 n=17 24 n=11 CR + PR CR

14 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION 0 5 10 15 20 25 30 35 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 n=46 CSU OLE: Continues to show increasing efficacy over time at 180mg Q8W 22.4 pt reduction in UAS7 at week 12 and 62% Complete Response rate observed at week 20 Data cut - off 11 Dec 2025 Mean UAS7 n=43 n=38 n=36 n=36 Week 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Response CR + WC CR n=38 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 n=46 n=43 n=36 n=36 n=34 Week n=34

15 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Briquilimab 180mg Q8W (n=63) Briquilimab well tolerated with favorable safety profile in the OLE study Low rate of safety/tolerability observations possibly related to KIT blockade in OLE Briquilimab 180mg Q8W (n=63) 1 (1.6%) Hair color change 39 (61.9%) Any Adverse Event* 2 (3.2) 3 Skin discoloration 2 (3.2) 1 Any Serious Adverse Event 1 (1.6) 2 Any adverse event leading to discontinuation 8 (12.7) Taste disorder/hypogeusia 2 (3.2) 4 Neutrophil count decreased 0 (0) Adverse event leading to death 0 (0) Any Treatment - Related TEAE ≥ Grade 3 1 (1.6) 5 WBC count decreased Median duration of follow up: 205 days *AEs occurring in ≥3 participants: nasopharyngitis, taste disorder, CoVID 19, fatigue 1. One case of large bowel obstruction, one case of breast injury, both unrelated 2. Grade 1 hypogeusia, related 3. Both reported as skin hyperpigmentation 4. One case related, one case unrelated to treatment. Both cases resolved while on treatment. 5. One case related, resolved while on treatment Data cut - off 11 Dec 2025

Conclusion and Next Steps Jeet Mahal, CEO

17 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Briquilimab complete response and well controlled disease at 12 weeks Note: These observations are derived from separate clinical settings; comparisons across trials are not based on head - to - head studies. 51% 38% Briquilimab CR & WC at Barzolvolimab CR & WC at Week 12 (UAS7=0 and UAS7<6) Week 12 (UAS7=0 and UAS7<6) 1 180mg Q8W Cohort 9.1 150mg Q4W 300mg Q8W (OLE) n=36 n=6 n=52 n=51 60 % 63 % 58% 67% 75% 0% 20% 40% 60% 80% 100% 1 Barzolvolimab Phase 2 CSU Topline Results

18 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Briquilimab demonstrated rapid and deep onset of disease control 45 Briquilimab (BEACON) Barzolvolimab (Phase II) 1 Placebo, n=21 Placebo, n=51 40 180mg Q8W (OLE), n=36 150mg Q4W, n=52 240mg single dose, n=5 300mg Q8W, n=51 35 360mg single dose, n=4 Cohort 9.1 (240mg . 180mg Q8W), n=6 30 25 20 15 10 5 0 0 1 2 3 4 5 6 7 8 9 10 11 12 Week Note: At Week 6 in the BEACON study, patients in the placebo arm were allowed rescue medications. Note: These observations are derived from separate clinical settings; comparisons across trials are not based on head - to - head studies. Mean UAS7 1 Barzolvolimab Phase 2 CSU Topline Results

19 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION January 2026 Chronic Urticaria Data Update Briquilimab demonstrates rapid efficacy and a favorable chronic safety profile • Rapid and durable clinical responses • Repeat dose safety data now available for more than 50 patients across BEACON and OLE studies • KIT related AEs continue to be predominantly low frequency, transient, low - grade events that resolved while on study Data gathered to - date sufficient to enable dose selection for CSU Phase 2b study • Targeting commencement of Phase 2b CSU study 2H 2026 Totality of data from BEACON, SPOTLIGHT and OLE support a compelling profile for briquilimab in chronic urticarias • Briquilimab’s unique drug properties allow for rapid disease control while minimizing KIT - related AEs

Jasper Therapeutics NASDAQ: JSPR January 2026